Tdspharm Co., Ltd. (KOSDAQ:464280)

Tdspharm Statistics

Total Valuation

Tdspharm has a market cap or net worth of KRW 45.12 billion. The enterprise value is 30.73 billion.

Market Cap	45.12B
Enterprise Value	30.73B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

Tdspharm has 5.53 million shares outstanding. The number of shares has increased by 14.22% in one year.

Current Share Class	5.53M
Shares Outstanding	5.53M
Shares Change (YoY)	+14.22%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	46.27%
Owned by Institutions (%)	4.27%
Float	2.95M

Valuation Ratios

The trailing PE ratio is 8.53.

PE Ratio	8.53
Forward PE	n/a
PS Ratio	1.48
PB Ratio	1.03
P/TBV Ratio	1.03
P/FCF Ratio	n/a
P/OCF Ratio	9.13
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 5.46, with an EV/FCF ratio of -3.70.

EV / Earnings	6.08
EV / Sales	1.01
EV / EBITDA	5.46
EV / EBIT	6.25
EV / FCF	-3.70

Financial Position

The company has a current ratio of 2.09, with a Debt / Equity ratio of 0.32.

Current Ratio	2.09
Quick Ratio	1.89
Debt / Equity	0.32
Debt / EBITDA	2.47
Debt / FCF	-1.68
Interest Coverage	19.71

Financial Efficiency

Return on equity (ROE) is 12.21% and return on invested capital (ROIC) is 13.56%.

Return on Equity (ROE)	12.21%
Return on Assets (ROA)	5.56%
Return on Invested Capital (ROIC)	13.56%
Return on Capital Employed (ROCE)	11.16%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.55
Inventory Turnover	7.31

Taxes

In the past 12 months, Tdspharm has paid 956.62 million in taxes.

Income Tax	956.62M
Effective Tax Rate	15.91%

Stock Price Statistics

The stock price has decreased by -30.43% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-30.43%
50-Day Moving Average	8,710.00
200-Day Moving Average	9,568.35
Relative Strength Index (RSI)	40.23
Average Volume (20 Days)	33,241

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Tdspharm had revenue of KRW 30.41 billion and earned 5.05 billion in profits. Earnings per share was 956.97.

Revenue	30.41B
Gross Profit	8.59B
Operating Income	4.92B
Pretax Income	6.01B
Net Income	5.05B
EBITDA	5.63B
EBIT	4.92B
Earnings Per Share (EPS)	956.97

Balance Sheet

The company has 28.30 billion in cash and 13.90 billion in debt, with a net cash position of 14.39 billion or 2,602.81 per share.

Cash & Cash Equivalents	28.30B
Total Debt	13.90B
Net Cash	14.39B
Net Cash Per Share	2,602.81
Equity (Book Value)	43.93B
Book Value Per Share	8,315.92
Working Capital	19.53B

Cash Flow

In the last 12 months, operating cash flow was 4.94 billion and capital expenditures -13.24 billion, giving a free cash flow of -8.30 billion.

Operating Cash Flow	4.94B
Capital Expenditures	-13.24B
Depreciation & Amortization	699.57M
Net Borrowing	730.82M
Free Cash Flow	-8.30B
FCF Per Share	-1,500.53

Margins

Gross margin is 28.24%, with operating and profit margins of 16.18% and 16.62%.

Gross Margin	28.24%
Operating Margin	16.18%
Pretax Margin	19.77%
Profit Margin	16.62%
EBITDA Margin	18.51%
EBIT Margin	16.18%
FCF Margin	n/a

Dividends & Yields

Tdspharm does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-14.22%
Shareholder Yield	-14.22%
Earnings Yield	11.20%
FCF Yield	-18.39%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Tdspharm has an Altman Z-Score of 3.97 and a Piotroski F-Score of 4.

Altman Z-Score	3.97
Piotroski F-Score	4